Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
NEW YORK (TheStreet) -- Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for today's trading.
Axovant Sciences (AXON): In an exclusive interview, Cramer sat down with Vivek Ramaswamy, president and CEO of Axovant, the biotech company whose IPO rallied over 99% in today's session on high hopes for the company's Alzheimer's treatments.
Ramaswamy said that while no one still fully understands how dementia in Alzheimer's patients really works, Axovant's drug, RVT-101, which it acquired from GlaxoSmithKline (GSK), is a unique drug that has shown amazing promise so far in Phase II testing and could potentially help millions of patients.
Ramaswamy continued by said that the drug, which is a once-a-day pill, has proven to be well tolerated and has improved both cognition and function in participants in the Phase II study. He expects to begin a six-month Phase III study later in 2015.